New hope for hodgkin lymphoma: drug combo could replace chemo in relapsed patients
NCT ID NCT07572123
First seen May 12, 2026 · Last updated Jun 20, 2026 · Updated 9 times
Summary
This clinical trial is for people whose Hodgkin lymphoma has returned or not responded to first treatment. It has two parts: one for standard-risk patients testing a combination of targeted drugs (brentuximab vedotin and nivolumab) plus radiation, and another for high-risk patients testing the immunotherapy pembrolizumab after a stem cell transplant. The goal is to see if these approaches work better than the usual high-dose chemotherapy and transplant. About 374 participants aged 5 to 75 will take part across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CLASSIC HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brentuximab vedotin, nivolumab, pembrolizumab
What this could lead to
If successful, this could offer more effective and less toxic treatment options for people with relapsed Hodgkin lymphoma, potentially improving survival without the need for intensive chemotherapy.
What could go wrong
This is a mid-stage trial (Phase 2/3) that hasn't started recruiting yet. The new combinations may not prove better than standard care, and side effects from immunotherapy or radiation could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.